Board of Directors
Roger Jeffs retired as President and co-CEO of United Therapeutics Corporation in 2016 after a successful 18-year tenure during which he led the company’s IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization “in recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children.”
Prior to joining United Therapeutics, Dr. Jeffs held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in Pharmacology from the University of North Carolina School of Medicine. In addition to Albireo, Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics.
-
David Chiswell, Ph.D. – ChairmanFormer CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP
-
Susan AlesinaVice President, National Business Development and Alliances, Boston Children’s Hospital
-
Ron CooperPresident and Chief Executive Officer
-
Habib DableFormer President and CEO, Acceleron Pharma; Currently Independent Director, Blueprint Medicines Corporation, and Venture Partner, RA Capital Management, L.P.
-
Michael Gutch, Ph.D.Chief Financial Officer, Noema Pharma
-
Stephanie S. Okey, M.S.Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company
-
Davey S. ScoonFormer CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors